1. Home
  2. RDI vs INTS Comparison

RDI vs INTS Comparison

Compare RDI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.18

Market Cap

23.6M

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$6.10

Market Cap

19.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
INTS
Founded
1937
2012
Country
United States
United States
Employees
2025
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
19.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RDI
INTS
Price
$1.18
$6.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$56.25
AVG Volume (30 Days)
24.0K
39.3K
Earning Date
04-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.19
52 Week High
$1.65
$8.06

Technical Indicators

Market Signals
Indicator
RDI
INTS
Relative Strength Index (RSI) 63.57 55.63
Support Level $0.98 $0.29
Resistance Level $1.48 $8.06
Average True Range (ATR) 0.05 0.42
MACD 0.01 -0.41
Stochastic Oscillator 95.29 11.69

Price Performance

Historical Comparison
RDI
INTS

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: